Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 6/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380250 | 0.92 | DRD3 (0.53) | AOC3PRMT5WDR77DRD3DRD2 | |
| SCHEMBL28500280 | 0.88 | ITGB3 (0.60) | AOC3ITGB3ITGA2B | |
| SCHEMBL29798701 | 0.88 | ITGB3 (0.60) | AOC3ITGB3ITGA2B | |
| SCHEMBL22713735 | 0.85 | AOC3 (0.69) | AOC3PRMT5WDR77DRD3DRD2 | |
| SCHEMBL29438671 | 0.85 | PRMT5 (0.51) | AOC3PRMT5WDR77DRD3DRD2 | |
| SCHEMBL471627 | 0.85 | PRMT5 (0.51) | AOC3PRMT5WDR77DRD3DRD2 | |
| SCHEMBL3693926 | 0.84 | DRD3 (0.56) | AOC3DRD3DRD2DRD4DRD1 | |
| SCHEMBL3653090 | 0.84 | HRH3 (0.64) | DRD2DRD4HRH3 | |
| SCHEMBL13201488 | 0.83 | PRMT5 (0.50) | AOC3PRMT5WDR77DRD3DRD2 | |
| Hydrochloric Acid SCHEMBL4535011 | 0.83 | HRH3 (0.62) | DRD2DRD4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664250-B2 | Cardiovascular disorders | BRISTOL-MYERS SQUIBB CO. | 2003-12-16 | — | — | US | disclosed |
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | S ATWAL KARNAIL (US) | 2003-06-19 | — | — | US | disclosed |
| US-6262068-B1 | ISOQUINOLONES | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | NPR3, SCN3A, NRDC | AOC3 11/4885PRMT5 3293/4885WDR77 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.